Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 14:20 save search
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Published: 2023-08-01 (Crawled : 14:20) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: -0.86%
H: 0.65%
C: -1.2%
covid-19 vaccine mrna collaboration study
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Published: 2023-07-27 (Crawled : 14:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.09%
H: 0.35%
C: -1.84%
pneumococcal vaccine merck trials
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
Published: 2023-06-27 (Crawled : 14:20) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 0.0%
H: 9.7%
C: -2.05%
vaccine universal
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
Published: 2023-04-06 (Crawled : 14:20) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: -0.7%
H: 4.23%
C: 1.69%
covid-19 candidate vaccine presentation trial
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
Published: 2023-02-15 (Crawled : 14:20) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: -1.11%
H: 4.38%
C: -1.12%
covid-19 collaboration vaccine trial phase 2
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
PSNL | $1.31 8.26% 7.63% 280K
|
Health Technology
|
| O: 1.64%
H: 37.54%
C: 26.21%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -2.05%
H: 3.47%
C: 0.3%
trials vaccine mrna agreement cancer
Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates
Published: 2023-02-01 (Crawled : 14:20) - globenewswire.com
BWV | $0.1802 5.44% 530K
|
|
| O: -2.44%
H: 8.33%
C: 4.17%
water partnership monkeypox vaccine blue marburg
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
DYAI A | $1.61 1.26% 1.24% 14K
|
Health Technology
|
| O: 5.52%
H: 1.74%
C: -1.17%
dyai-100 covid-19 candidate antibody vaccine trial response
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 1.53%
H: 8.47%
C: -1.19%
covid-19 vaccine approved nuvaxovid
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
Published: 2022-12-14 (Crawled : 14:20) - biospace.com/
DYAI A | $1.61 1.26% 1.24% 14K
|
Health Technology
|
| O: 10.17%
H: 3.85%
C: -5.38%
dyai-100 covid-19 vaccine study
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine
Published: 2022-12-01 (Crawled : 14:20) - biospace.com/
BWV | $0.1802 5.44% 530K
|
|
| O: 0.0%
H: 5.51%
C: 0.39%
water vaccine blue update
Vaccine Cold Chain Logistics Market Expected to Reach US$ 4.90 Billion by 2030 - Growing Beyond COVID-19 Application
Published: 2022-11-23 (Crawled : 14:20) - prnewswire.com
FDX 4 | $266.99 1.37% -0.24% 1.7M
|
Transportation
|
| O: 0.08%
H: 0.61%
C: 0.31%
covid-19 growing vaccine application expected market
VBI Vaccines to Participate in Upcoming Investor Conferences - November 14, 2022
Published: 2022-11-14 (Crawled : 14:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.45%
H: 6.67%
C: 3.33%
vaccine
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-10 (Crawled : 14:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -0.73%
H: 11.01%
C: -1.16%
financial update results vaccine
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: -1.5%
H: 2.67%
C: -1.15%
vaccine breast symposium trial presentation cancer
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -3.96%
H: 8.79%
C: 5.31%
covid-19 vaccine prototype trial
BioIVT Announces Global eCommerce Collaboration With Charles River Laboratories Avian Vaccine Services
Published: 2022-10-03 (Crawled : 14:20) - biospace.com/
CRL | $226.78 -0.34% 0.0% 410K
|
Commercial Services
|
| O: 0.55%
H: 4.48%
C: 2.98%
global services collaboration vaccine
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Published: 2022-08-31 (Crawled : 14:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.75%
H: 1.98%
C: 1.98%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.35%
H: 0.6%
C: -1.7%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.63%
H: 1.42%
C: -2.27%
covid-19 fda vaccine granted authorization
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17
Published: 2022-08-26 (Crawled : 14:20) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -0.03%
H: 1.53%
C: -5.48%
covid-19 vaccine granted authorization
Pfizer and BioNTech Push Hard on Omicron-Specific Vaccine While Fending Off Lawsuits
Published: 2022-07-27 (Crawled : 14:20) - biospace.com/
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.28%
vaccine
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.